Nautilus Biotechnology, Inc. (NAUT) Form 10-Q — Oct 27, 2026
Nautilus Biotechnology filed its Q3 2026 10-Q reporting its first revenue of $0.4 million for the nine months ended September 30, 2026, driven by grant revenue from The Michael J. Fox Foundation and early Early Access Program service sales. The company posted a net loss of $44.8 million (EPS -$0.35), roughly flat versus $45.2 million a year ago, and holds $114.3 million in cash, cash equivalents and investments, which management says funds operations for at least the next 12 months.
Key figures
- Revenue
- 424000
- Guidance
- Company expects cash, cash equivalents, and investments sufficient to fund operations for at least the next 12 months; commercial launch planned early 2027 with pre-orders, instrument shipments beginning mid 2027.
- Total Assets
- 148924000
- Cash Position
- 114300000
- Shares Outstanding
- 127328617
- Q3 revenue
- 234000
- Atm capacity
- 125000000
- Shelf capacity
- 300000000
- Accumulated deficit
- 376800000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.